Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study
Objective: Evaluate the efficacy and safety of IPX203 vs. immediate-release (IR) carbidopa-levodopa (CD-LD) and vs. extended-release (ER) CD-LD (IPX066, RYTARY®) in patients with advanced Parkinson’s…Impact and communication of OFF periods in Parkinson disease
Objective: To review existing literature on the impact and communication of OFF periods for patients with Parkinson disease (PwP) and carepartners. Background: Studies show associations…Post-hoc analyses of the recommended starting dose for Rytary based on “off” time
Objective: To determine whether correcting for “off” time duration improves the selection of the final LD dose when converting to extended-release carbidopa-levodopa capsules (ER CD-LD,…The Personal Kinetigraph Fluctuator Score Identifies Motor Fluctuations in Parkinson’s disease
Objective: To evaluate the Personal Kinetigraph (PKG) fluctuator score (FS) in detecting motor fluctuations in Parkinson's disease (PD) patients. Background: Fluctuations of response to levodopa,…Wearable sensors and decision algorithms for advanced therapy referral in Parkinson’s disease
Objective: Pilot study to determine the impact of remote monitoring using objective, wearable sensors on the advanced therapy referral rate in patients with advanced Parkinson's…Rotigotine transdermal patch in Chinese patients with advanced Parkinson’s disease: A randomized, double-blind study
Objective: A multicenter phase III study (SP1037; NCT01646255) to investigate the efficacy and safety of rotigotine in Chinese patients with advanced Parkinson's disease (PD). Background:…Status of NPF-QII after six years: Updates to the dataset
Objective: To describe the status and recent findings from the National Parkinson Foundation's Quality Improvement Initiative (NPF-QII), an 8,179 subject observational clinical study conducted at…Multiple system atrophy with motor fluctuations: A presynaptic disease variant?
Objective: To describe a case-series of Parkinsonian multiple system atrophy (MSAp) firstly diagnosed with Parkinson's disease (PD) due to clear-cut and severe l-dopa-induced motor fluctuations…Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience
Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations
Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- 24
- Next Page »